Acute and Prolonged Effects of Dermal Suction on Joint Range of Motion and Passive Muscle Stiffness: A Preliminary Study

This study aimed to investigate the acute and prolonged effects of dermal suction on joint range of motion (ROM) and passive muscle stiffness. Eight-minute dermal suction was prescribed for the quadriceps femoris in 15 participants. Hip extension ROM, knee flexion ROM, and passive muscle stiffness of the rectus femoris (RF) and vastus lateralis (VL) were measured before and immediately, 30 min, 60 min, 120 min, 24 h, and 48 h after dermal suction. Passive muscle stiffness was measured using shear wave elastography. Hip extension ROM significantly increased immediately (p = 0.032), 60 min (p = 0.029), and 120 min (p = 0.031) after dermal suction compared with before dermal suction; however, it was not significantly different at 30 min, 24 h, and 48 h after dermal suction (p > 0.05). Passive muscle stiffness of the RF and VL and knee flexion ROM did not significantly change at any measurement time compared with before dermal suction (p > 0.05). Our preliminary results suggest that dermal suction improves hip extension ROM immediately after dermal suction of the quadriceps femoris, followed by a return to the pre-prescription level 30 min after. However, the effect was prolonged for 120 min and disappeared before 24 h

Effectiveness of an erbium-doped:yttrium, aluminum and garnet laser for treatment of peri-implant disease : clinical, microbiological, and biochemical marker analyses

The effectiveness of an erbium-doped: yttrium, aluminum and garnet (Er: YAG) laser (EYL) for the treatment of peri-implant disease (PID) remains unclear. The aim of this study was to compare non-surgical EYL therapy for PID with locally delivered minocycline hydrochloride (MC) ointment therapy by evaluating clinical, microbiological, and biochemical markers. Thirty-seven patients with PID were randomly assigned to either the EYL group (n = 18) or the MC group (n = 19). The clinical, microbiological, and biochemical markers at baseline and at 1 and 3 months after treatment were compared between the two groups. Subgingival plaque and peri-implant crevicular fluid (PICF) were collected from the diseased pockets. In the EYL group, probing pocket depth (PPD) was significantly decreased after treatment when compared with baseline. On the other hand, in the MC group, there was no significant decrease in PPD after treatment. Specific bacteria associated with PID were not determined. The counts of both Gram-positive and -negative species did not significantly decrease in the EYL group at 3 months after treatment. In the MC group, the counts of almost all bacterial species were significantly decreased after treatment. Biochemical marker analysis of PICF revealed significantly lower levels of metalloproteinase (MMP)-9 in the EYL group, as compared with the MC group at 3 months after treatment (p= 0.009). Non-surgical therapy with an EYL for PID was clinically effective, with decreased MMP-9 levels in PICF, which may lead to reduced peri-implant tissue destruction

Periodontal Tissue Regeneration Using Fibroblast Growth Factor -2: Randomized Controlled Phase II Clinical Trial

Background: The options for medical use of signaling molecules as stimulators of tissue regeneration are currently limited. Preclinical evidence suggests that fibroblast growth factor (FGF)-2 can promote periodontal regeneration. This study aimed to clarify the activity of FGF-2 in stimulating regeneration of periodontal tissue lost by periodontitis and to evaluate the safety of such stimulation. Methodology/Principal Findings: We used recombinant human FGF-2 with 3% hydroxypropylcellulose (HPC) as vehicle and conducted a randomized double-blinded controlled trial involving 13 facilities. Subjects comprised 74 patients displaying a 2- or 3-walled vertical bone defect as measured ?3 mm apical to the bone crest. Patients were randomly assigned to 4 groups: Group P, given HPC with no FGF-2; Group L, given HPC containing 0.03% FGF-2; Group M, given HPC cotaining 0.1% FGF-2; and Group H, given HPC Containing 0.3% FGF-2. Each patient underwent flap operation during which we administered 200 μL of the appropriate investigational drug to the bone defect. Before and for 36 weeks following administration, patients underwent periodontal tissue inspections and standardized radiography of the region under investigation. As a result, a significant difference (p = 0.021) in rate of increase in alveolar bone height was identified between Group P (23.92%) and Group H (58.62%) at 36 weeks. The linear increase in alveolar bone height at 36 weeks in Group P and H was 0.95 mm and 1.85 mm, respectively (p = 0.132). No serious adverse events attribute to the investigational drug were identified. Conclusions: Although no statistically significant differences were noted for gains in clinical attachment level and alveolar bone gain for FGF-2 groups versus Group P, the significant difference in rate of increase in alveolar bone height (p = 0.021) between Groups P and H at 36 weeks suggests that some efficacy could be expected from FGF-2 in stimulating regeneration of periodontal tissue in patients with periodontitis

High Concentrations of Pyridinoline in Gingival Crevicular Fluid of Patients with Periodontitis and Gingivitis

骨コラーゲンに特有の架橋物質であるビリジノリン,デオキシピリジノリンのELISA法による微量測定が可能になり,骨吸収マーカーとして骨粗鬆症などの骨疾患の診断に用いられている.本研究は歯肉溝滲出液サンプルを採取してピリジノリンを測定し,歯槽骨吸収活性マーカーとしての評価を行うことを目的とした.歯肉炎には本学学生12名を被験者とした.前歯あるいは小臼歯部頬側から滲出液採取を行った.歯周炎には成人性歯周炎と診断された歯周病の患者11名,急性歯周膿瘍症状を呈する9名から滲出液を採取した.採取部位を簡易防湿後, Micro Capillary Tubeにて滲出液を採取した後, ELISA法を用いたキットにて吸光度を測定し,標準曲線よりピリジノリン値を算出した.滲出液中のピリジノリン量は,急性歯周膿瘍>歯周炎>歯肉炎の順で高値を示した.滲出液ピリジノリンが高い確率で歯槽骨吸収活性を示す指標になる事が判明したことから歯肉炎から歯周炎への移行を判断する有力な材料となるものと考えられる.Serum and urinary concentrations of pyridinoline (PYD) are used as specific markers of bone resorption in various systemic diseases. The purpose of the present study was to determine PYD levels in gingival crevicular fluid (GCF) of patients with periodontitis and gingivitis. GCF was collected from the buccal gingival sulcus of the study tooth from patients with periodontitis (n=11), periodontitis with periodontal abscess (n=9) and gingivitis (n=12) using microcapillary tubes. PYD was measured by the inhibition ELISA method. The mean PYD concentration in patients with periodontitis (4.2±0.6 nmol/L, ±SD) was significantly higher than in those with gingivitis (2.5±0.8 nmol/L, p<0.01). The highest levels were found in GCF of patients with periodontitis associated with abscess formation (6.6±0.9 nmol/L, p<0.01). Our results suggested that PYD levels in GCF could be a potentially useful marker of alveolar bone remodeling in human periodon tal diseases.11KJ00004267166原著ORIGINAL ARTICLEdepartmental bulletin pape